HerDox also compared favourably against lipodox and empty particles on HER3+ human lines derived from TNBC, glioblastoma and malignant melanoma (whose high HER3/ErbB3 expression echo clinical specimens of malignant and metastatic melanoma, several types of brain tumours, invasive breast carcinoma and TNBC; Supplementary Figs. 10–13), bone-metastatic prostate cancer, ovarian (including chemoresistant) cancer, and Herceptin-resistant HER2+ breast cancer especially compared with Herceptin (Tz; Supplementary Fig. 14). This evidence concerns the gene ERBB3 and breast carcinoma.